Evidence map›Paper›PMID 40721579›Full record

ArticleNature communications2025

Combatting virulent gut bacteria by inhibiting the biosynthesis of a two-component lanthipeptide toxin.

Ryan Moreira, Bidisha Chakraborty, Yi Yang, Chandrashekhar Padhi, Michael S Gilmore, Satish K Nair, Wilfred A van der Donk

Abstract read
In one paragraph

Article in Nature communications, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Frontiers in microbiology · 2026
    Article
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Ryan MoreiraDepartment of Chemistry and Howard Hughes Medical Institute, University of Illinois at Urbana-Champaign, Urbana, IL, USA.ORCID http://orcid.org/0000-0003-0694-219X
Bidisha ChakrabortyCenter for Biophysics and Quantitative Biology, University of Illinois at Urbana-Champaign, Urbana, IL, USA.ORCID http://orcid.org/0000-0001-6896-2423
Yi YangDepartment of Chemistry and Howard Hughes Medical Institute, University of Illinois at Urbana-Champaign, Urbana, IL, USA.ORCID http://orcid.org/0009-0009-7467-0641
Chandrashekhar PadhiDepartment of Chemistry and Howard Hughes Medical Institute, University of Illinois at Urbana-Champaign, Urbana, IL, USA.ORCID http://orcid.org/0009-0009-1305-0377
Michael S GilmoreDepartments of Ophthalmology and Microbiology, Harvard Medical School, Boston, MA, USA.ORCID http://orcid.org/0000-0001-6389-832X
Satish K NairDepartment of Chemistry and Howard Hughes Medical Institute, University of Illinois at Urbana-Champaign, Urbana, IL, USA. snair@illinois.edu.ORCID http://orcid.org/0000-0003-1790-1334
Wilfred A van der DonkDepartment of Chemistry and Howard Hughes Medical Institute, University of Illinois at Urbana-Champaign, Urbana, IL, USA. vddonk@illinois.edu.ORCID http://orcid.org/0000-0002-5467-7071

Funding

Training and OutreachP30GM124166 · NIGMS · CORNELL UNIVERSITY · PI RICHARD A. CERIONE · 2019 to 2026
$28.3M
Structure, Function, and Engineering of RiPP Biosynthetic EnzymesR35GM151874 · NIGMS · UNIVERSITY OF ILLINOIS AT URBANA-CHAMPAIGN · PI Satish K Nair · 2024 to 2026
$1.8M
4800 Plus MALDI TOF/TOF AnalyzerS10RR027109 · NCRR · UNIVERSITY OF ILLINOIS AT URBANA-CHAMPAIGN · PI VAN DER DONK, WILFRED A. · 2010 to 2010
$395k
NCRR NIH HHS S10 RR027109NIGMS NIH HHS P30 GM124166NIGMS NIH HHS R35 GM151874U.S. Department of Health & Human Services | NIH | National Center for Research Resources (NCRR) S10 RR027109 AU.S. Department of Health & Human Services | NIH | National Institute of General Medical Sciences (NIGMS) R35GM151874
6 · The paper itself

Abstract

The enterococcal cytolysin is a toxic, two-component ribosomally synthesized and post-translationally modified peptide (RiPP) produced by pathogenic Enterococcus faecalis. Cytolysin-producing (C+) E. faecalis resides in the gut microbiome in a commensal role, but results in negative clinical outcomes in alcoholic hepatitis patients. To potentially combat cytolysin virulence, we report inhibitors of its maturation. An extracellular serine protease CylA that is essential for toxin activation is chosen as target. A series of α-aminopeptide boronic acids are designed and synthesized that block cytolysin maturation at low micromolar to nanomolar concentrations in vitro. A crystal structure of CylA provides insights into substrate recognition, autocatalytic activation of the enzyme, and toxin maturation. The inhibitors block hemolytic activity, reduce the amount of cytolysin, and attenuate expression of the cytolysin biosynthetic gene cluster without impeding cell growth. These studies provide a potential route to the development of treatments for cytolysin-induced disease states.

Indexed as

Bacterial ProteinsBacterial ToxinsEnterococcus faecalisGastrointestinal MicrobiomePerforinCrystallography, X-RayHumansMultigene FamilyVirulenceBacterial ProteinsBacterial ToxinsPerforin

Identifiers

PMID40721579
PMCPMC12304293

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.